The role of IgA and IgA Fc receptors as anti-inflammatory agents.
METHODS
Serum monomeric immunoglobulin A (IgA) has powerful immunomodulatory roles in its ability to suppress immune responses. Monomeric IgA acts through FcalphaRI, which plays a significant role in vivo in maintaining the integrity of immune responses by an inhibitory immunoreceptor tyrosine-based activation motif-mediated process and powerful inhibitory cellular effector mechanisms elicited by the IgA system.


RESULTS
Triggering of FcalphaRI-mediated inhibitory function by Fab anti-FcalphaRI-mediated inhibitory function is able to inhibit several inflammatory and autoimmune diseases including asthma and glomerulonephritis.


CONCLUSIONS
The use of monomeric IgA as a therapeutic tool in human inflammatory diseases may offer much potential.
Monteiro
Renato C
RC
Inserm U699, Paris, France. renato.monteiro@inserm.fr
D020816:Amino Acid Motifs; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D007249:Inflammation / Q000276:immunology / Q000628:therapy; D051379:Mice; D018448:Models, Immunological; D010766:Phosphorylation / Q000276:immunology; D011499:Protein Processing, Post-Translational / Q000276:immunology; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6 / Q000502:physiology; D051076:Proto-Oncogene Proteins c-fyn / Q000502:physiology; D011961:Receptors, Fc / Q000276:immunology / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015703:Antigens, CD; C036832:Fc(alpha) receptor; D007070:Immunoglobulin A; D011961:Receptors, Fc; D051076:Proto-Oncogene Proteins c-fyn; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6
Clin Exp Immunol. 2005 Jun;140(3):478-90
15932509
J Pathol. 2006 Jan;208(2):270-82
16362985
Immunol Rev. 2009 Nov;232(1):59-71
19909356
J Clin Invest. 1975 Feb;55(2):368-76
1127105
Trends Immunol. 2003 Feb;24(2):55-8
12547499
Immunity. 2005 Jan;22(1):31-42
15664157
J Mol Biol. 1999 Mar 12;286(5):1421-47
10064707
Kidney Int. 1998 May;53(5):1321-35
9573548
J Biol Chem. 1999 Mar 12;274(11):7216-25
10066783
Annu Rev Immunol. 2008;26:513-33
18370923
Blood. 1994 Mar 1;83(5):1278-88
8118031
Immunol Rev. 2002 Dec;190:123-36
12493010
J Leukoc Biol. 1995 Jun;57(6):875-82
7790770
J Clin Immunol. 2008 May;28 Suppl 1:S56-61
18202833
Clin Exp Immunol. 1996 Sep;105(3):537-43
8809146
Clin Exp Immunol. 1978 Dec;34(3):423-8
369752
Cell Immunol. 1978 Mar 15;36(2):363-76
343924
Annu Rev Immunol. 2003;21:177-204
12524384
J Immunol. 2008 Feb 15;180(4):2669-78
18250479
Biochem J. 1990 Oct 15;271(2):285-96
2241915
J Exp Med. 1976 Nov 2;144(5):1227-42
825608
J Immunol. 2001 Feb 1;166(3):1781-9
11160224
J Leukoc Biol. 1998 May;63(5):636-42
9581809
Nature. 2003 Jun 5;423(6940):614-20
12768205